02 Mar 2019 Halozyme Announces FDA Approval Of Herceptin Hylecta
02 Mar 2019 AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI™) for the Treatment of Moderate to Severe Plaque Psoriasis
01 Mar 2019 ImmunoGen Announces Top-Line Results from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer
28 Feb 2019 Fosun Pharma Has Opened a New Era for Biosimilar in China Henlius Receives NMPA Approval for Its First Product HLX01
27 Feb 2019 Janssen Announces U.S. FDA Approval of Novel TREMFYA® (guselkumab) One-Press Patient-controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis
27 Feb 2019 Scholar Rock Announces Positive Interim Results from Phase 1 Trial of SRK-015 in Healthy Volunteers and Updates on Future Development Plans
27 Feb 2019 TG Therapeutics Announces Initiation of Phase I First-in-Human Clinical Trial of its Anti-CD47/CD19 Bispecific Antibody, TG-1801, in Patients with Relapsed or Refractory B-cell Lymphoma
27 Feb 2019 Equillium Announces Plan to Develop EQ001 for the Treatment of Lupus Nephritis
25 Feb 2019 Genmab Announces Positive Topline Results in Phase III COLUMBA Study of Subcutaneous Daratumumab
25 Feb 2019 Positive results presented from two Phase 3 trials of Dupixent® (dupilumab) in severe chronic rhinosinusitis with nasal polyps
24 Feb 2019 Alder BioPharmaceuticals® Submits Biologics License Application to the U.S. Food and Drug Administration for Eptinezumab
24 Feb 2019 FDA Grants Priority Review and Accepts sBLA of SOLIRIS® (Eculizumab) as a Treatment for Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
21 Feb 2019 ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
21 Feb 2019 Five Prime Therapeutics Doses First Patient in Phase 1b Trial of FPA150
20 Feb 2019 Fusion Pharma Announces First Patient Dosing in a Phase 1 Clinical Trial of [225Ac]-FPI-1434 Injection in Patients with Advanced Solid Tumors
20 Feb 2019 Gliknik To Receive $15 Million Milestone Payment From Pfizer Inc. Following Clinical Progress With PF-06755347, Previously Known As GL-2045
20 Feb 2019 Xencor Announces Partial Clinical Hold on Phase 1 Study of XmAb14045
20 Feb 2019 FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) Monotherapy for Third-Line Treatment of Patients with Advanced Small Cell Lung Cancer (SCLC)
20 Feb 2019 Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
20 Feb 2019 Pfizer Receives European Approval for ZIRABEV (bevacizumab), a Biosimilar to Avastin
20 Feb 2019 Merck Provides Update on KEYNOTE-240, a Phase 3 Study of KEYTRUDA® (pembrolizumab) in Previously Treated Patients with Advanced Hepatocellular Carcinoma
20 Feb 2019 Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-105, a Novel Multispecific PD-L1 and 4-1BB Antibody
19 Feb 2019 FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node(s) Following Complete Resection
19 Feb 2019 FDA Grants Priority Review to Genentech’s Polatuzumab Vedotin in Previously Treated Aggressive Lymphoma
18 Feb 2019 Rainier Therapeutics Presents Data on Vofatamab in Patients with Advanced Urothelial Cell Carcinoma (Bladder Cancer) Previously Treated with Chemotherapy at ASCO GU 2019

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up